Partner with us
We’re committed to building sustainable relationships across the scientific and business communities that help us combine transformative advances in the understanding of human disease with the science of therapeutics, all with the goal of advancing human health.
We’re committed to building sustainable relationships across the scientific and business communities that help us combine transformative advances in the understanding of human disease with the science of therapeutics, all with the goal of advancing human health.
Collaboration defines our culture
We know that collaborating with the world’s experts is a cornerstone to solving some of science’s most difficult problems. Collaboration is one of our core values at Vertex — it defines our culture.
Externally, our collaborations with companies, academia, research organizations and nonprofit organizations help drive scientific innovation and the development of new medicines.
Internally, it creates an environment that encourages the open exchange of ideas and provides the freedom for our talented employees to explore new scientific concepts. Our Vertex Opportunities for Intrapreneurship & Corporate Evolution (VOICE) program is a great example. Check it out here.
Partnerships enhance scientific innovation
To support our mission, we seek external partnerships that promote scientific innovation, and we’re focused on creating relationships that are grounded in deep biological knowledge of a disease and target. We believe that innovation should not be limited to opportunities based solely on specific stages of development or on particular treatment modalities.
Our current priorities include:
-
Supporting Vertex’s cystic fibrosis strategy of bringing innovative medicines to patients by complementing our existing research efforts and clinical assets with additional tools and/or technologies.
-
Diversifying our portfolio with potentially transformative medicines in diseases where there is a high unmet need.
-
Leveraging cutting-edge technology platforms to accelerate the discovery of new disease targets, compounds, delivery mechanisms and potential treatment modalities.
-
Maximizing the potential of Vertex assets by using strategic collaborations and licensing opportunities to enable speedy and thorough development.
Vertex is a trusted partner
We value developing strategic relationships that are mutually beneficial. Our approach is to create successful partnerships with well-articulated principles and value propositions. Our portfolio of alliances consists of a variety of collaboration models to meet the different needs of our partners.
Vertex works to maximize the value of our partnerships for both organizations, seeking to make decisions that align our common goals and, most importantly, bring benefits to patients as quickly as possible. We work collaboratively to make informed and strategic decisions to rapidly progress our partnered programs.
Areas of interest
We're actively exploring all approaches that may change the treatment of a serious disease where no adequate treatment currently exists. We are seeking technologies that will enable exploration of new diseases or disease targets.
Please also contact us if you'd like to explore a potential partnership related to any of the following:
Our global network of innovation
Targets and Human Cell Models
Genomics plc
August 30, 2018 announcement
Innovation in Small Molecule Therapeutics
X-Chem
January 4, 2019 announcement
Kymera
May 15, 2019 announcement
Ribometrix
September 30, 2019 announcement
Skyhawk Therapeutics
December 22, 2020 announcement
Stablix
April 25, 2023 announcement
Cell and Genetic Therapies
CRISPR Therapeutics
April 20, 2021 announcement
Affinia Therapeutics
April 27, 2020 announcement
Arbor Biotechnologies
January 3, 2019 announcement
Mammoth Biosciences
October 26, 2021 announcement
Obsidian Therapeutics
April 22, 2021 announcement
Verve Therapeutics
July 20, 2022 announcement
Entrada Therapeutics
December 8, 2022 announcement
Tevard Biosciences
February 28, 2023 announcement
ImmunoGen
March 1, 2023 announcement
Lonza
June 26, 2023 announcement